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Abstract
Background: Pluripotent stem cells are attractive progenitor cells for the generation of erythroid cells in vitro as have
expansive proliferative potential. However, although embryonic (ESC) and induced pluripotent (iPSC) stem cells can be
induced to undergo erythroid differentiation, the majority of cells fail to enucleate and the molecular basis of this
defect is unknown. One protein that has been associated with the initial phase of erythroid cell enucleation is the
intermediate filament vimentin, with loss of vimentin potentially required for the process to proceed.
Methods: In this study, we used our established erythroid culture system along with western blot, PCR and
interegation of comparative proteomic data sets to analyse the temporal expression profile of vimentin in erythroid
cells differentiated from adult peripheral blood stem cells, iPSC and ESC throughout erythropoiesis. Confocal
microscopy was also used to examine the intracellular localisation of vimentin.
Results: We show that expression of vimentin is turned off early during normal adult erythroid cell differentiation, with
vimentin protein lost by the polychromatic erythroblast stage, just prior to enucleation. In contrast, in erythroid cells
differentiated from iPSC and ESC, expression of vimentin persists, with high levels of both mRNA and protein even in
orthochromatic erythroblasts. In the vimentin-positive iPSC orthochromatic erythroblasts, F-actin was localized around
the cell periphery; however, in those rare cells captured undergoing enucleation, vimentin was absent and F-actin was
re-localized to the enucleosome as found in normal adult orthrochromatic erythroblasts.
Conclusion: As both embryonic and adult erythroid cells loose vimentin and enucleate, retention of vimentin by iPSC
and ESC erythroid cells indicates an intrinsic defect. By analogy with avian erythrocytes which naturally retain vimentin
and remain nucleated, retention in iPSC- and ESC-derived erythroid cells may impede enucleation. Our data also
provide the first evidence that dysregulation of processes in these cells occurs from the early stages of differentiation,
facilitating targeting of future studies.
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Introduction
The generation of red blood cells in vitro as an alterna-
tive clinical product is of interest to blood services glo-
bally. Peripheral blood, cord blood, induced pluripotent
(iPSC) and embryonic stem cells (ESC) have been used
as progenitors in erythroid culture systems, all differenti-
ating along the erythroid pathway [1–5]. However, eryth-
roid cells differentiated from adult peripheral blood and
cord blood stem cells have a restricted expansion poten-
tial using current systems [6]. In contrast, pluripotent
stem cells (ESC and iPSC) have the potential to provide
an inexhaustible source of progenitors for the generation
of large numbers of erythroid cells. In particular, explor-
ation of iPSC as a progenitor source is attractive as they
can be derived from easily accessible adult cells, and
without the associated ethical issues of ESCs, opening
up opportunities for autologous transfusion products.
However, in comparison to the high proportion of enu-
cleated reticulocytes achieved from adult and cord blood
progenitors, up to 95% [2, 5], enucleation rates for eryth-
roid cells differentiated from ESC and iPSC are low, ≤
10% [1, 3, 4, 7, 8]. An increased yield of erythroid cells
from iPSC and ESC has been achieved using a
multi-step differentiation protocol to mimic and surpass
the early stages of development; however, enucleation
rates remained low [9]. Although a markedly higher enu-
cleation rate for ESC line H1 has been reported in one
paper [3], it could not be achieved for ESC line H9 in
the same study, or for H1 in other studies [7]. The mo-
lecular basis of the enucleation defect therefore requires
much further investigation to enable rectification before
these cells can be considered as a reliable source for
therapeutic applications.
Red blood cell enucleation is a continuous multi-step
process (reviewed by Migliaccio and Keerthivasan et al.
[10, 11]); the molecular details of which are still un-
defined, although recent advances have been made in
elucidating the process [2, 10, 12, 13]. One protein that
has been associated with the initial phase of enucleation
is the intermediate filament vimentin, which forms part
of the radial and juxtanuclear intermediate filament net-
work. Vimentin plays an important role in supporting
the intracellular organelles, especially the nucleus, with
filaments extending from the nuclear periphery to the
cell membrane, anchoring the nucleus in the cytoplasm
of the cells [14].
Notwithstanding, in non-erythroid cells, vimentin’s
role in orchestrating a wide range of cellular events is
exemplified by its involvement in cell migration and ad-
hesion [15, 16], interaction with signalling proteins [17]
and in cytoskeleton cross-talk [18].
In murine erythroleukemia (MEL) cells, there is a
marked and rapid loss of vimentin when the cells are
chemically induced to differentiate [19]. Similarly,
murine embryonic erythroid cells lose vimentin late in
differentiation [20]; both these and human embryonic
erythroid cells are now known to enucleate [21, 22]
(reviewed by Palis 2014 [23]) and vimentin is absent in
murine definitive erythrocytes [20]. There is little data in
the literature addressing the expression of vimentin in
human erythroblasts. One early study described vimen-
tin unusually as non-filamentous in structure, and al-
though absent in mature erythrocytes, its loss during
erythroid maturation as random rather than related to a
stage of differentiation [24]. In contrast, vimentin is
retained in avian erythrocytes which are nucleated, an-
choring the nucleus within the cell [25], suggesting a
role for vimentin regulation in enucleation.
In this study, we show in adult erythropoiesis vimentin
mRNA is lost early during the differentiation process,
with a precipitous loss in protein levels between baso-
philic and polychromatic erythroblasts, prior to enucle-
ation. In contrast in erythroid cells differentiated from
the ESC line RC9 and iPSC line C19 expression of
vimentin continues, with high levels of both mRNA and
protein detected even in orthochromatic erythroblasts.
In adult orthochromatic erythroblasts undergoing enu-
cleation F-actin is re-located to the enucleosome struc-
ture. In contrast in the majority of vimentin-positive
iPSC orthochromatic erythroblasts, F-actin remained lo-
calized around the cell periphery. However, in the very
rare cells captured undergoing enucleation, vimentin
was absent, and F-actin was localized to the same enu-
cleosome structure. Although inconclusive because of
the low enucleation rate and thus difficulty in capturing
cells undergoing enucleation at any one time, it is tempt-
ing to speculate a link between vimentin retention and
failure of actin re-localisation, the proteins being known
to interact.
As both embryonic (primitive) and adult (definitive)
erythroid cells enucleate and loose vimentin, retention
of vimentin by erythroid cells differentiated from iPSC
and ESC is an intrinsic defect. By analogy with avian
erythrocytes which also retain vimentin and are nucle-
ated, aberrant retention of vimentin in iPSC- and
ESC-derived erythroid cells may impede their enucle-
ation. Importantly, our data also provides the first indi-
cation that dysregulation of processes in these iPSC and
ESC erythroid cells occurs from, at least, the early stages
of erythroid differentiation.
Materials and methods
Cell isolation and culture
Haematopoietic differentiation of the ESC line RC9 [26]
and iPSC line C19 [27] and isolation of CD34+ cells were
performed as described previously [4, 9, 27]. Adult per-
ipheral blood CD34+ cells were isolated as described
previously [2].
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Adult, C19 and RC9 CD34+ cells were cultured in a
three-stage erythroid culture system [2]. In brief, the
base medium consisted of Iscove’s modified Dulbecco’s
medium (IMDM, Source BioScience, Nottingham, UK)
containing 3% (v/v) AB Serum (Sigma-Aldrich, Poole,
UK), 2% FCS (Hyclone; GE Healthcare SH30071.03),
10 μg ml−1 insulin (Sigma-Aldrich), 3 Uml−1 heparin
(Sigma-Aldrich), 200 μg ml−1 transferrin (R&D Systems,
Abingdon, UK) and 3 Uml−1 Epo (Roche, Welwyn Gar-
den City, UK). The first stage was supplemented with
10 ng ml−1 stem cell factor (SCF, Medsafe, Sweden) and
1 ng ml−1 IL-3 (R&D Systems, Abingdon, UK), the sec-
ond stage with 10 ng ml−1 SCF and the final stage with
an additional 300 μg ml−1 transferrin. RC9 CD34+ cells
were co-cultured with OP9 cells from days 0–7 in Stem-
line (Sigma) containing 1 μM hydrocortisone, 50 ng ml−1
SCF, 16.7 ng ml−1 Flt3L, 6.7 ng ml−1 BMP4, 6.7 ng ml−1
IL3, 6.7 ngml−1 IL11, 3 Uml−1 EPO, 50 uM IBMX and
10% FCS. After day 7, cells were co-cultured with OP9
in Iscove (Biochrom) containing 1% BSA, 10 μg ml−1 in-
sulin, 0.2 mgml−1 transferrin, 0.1 mM
β-mercaptoethanol, 1× lipid (peprotech), 1 μM hydrocor-
tisone, 20 ng ml−1 SCF, 20 ngml−1 IGF-1, 6.7 ng ml−1
IL3, 6.7 ng ml−1 IL11, 3 Uml−1 EPO and 10% FCS.
We have previously shown pluripotency proteins
Oct-4, SOX-2 and KLF-4 are lost in erythroid cells dif-
ferentiated from the C19 iPSC line [4], and expression of
pluripotency markers SSEA4, SSEA3 and TRA 1-60 are
lost from erythroid cells differentiated from the RC9
ESC line [9]. We have further compared the expression
of Oct-4, SOX-2 and NANOG in erythroid cells differ-
entiated from ESC lines RC9 and H1 with that of
stage-matched adult erythroid cells, which shows high
levels of expression in the undifferentiated stem cells, as
expected, but by 10 days of erythroid differentiation
levels are equivalent to that in the adult cells (Add-
itional file 1: Figure S1).
Adult orthochromatic erythroblasts were isolated fol-
lowing incubation with tetramethylrhodamine methyl
ester (TMRM). Cells at day 16 in culture were dual la-
belled with Hoechst 33342 (5 μg/ml) and TMRM (25
nM). Orthochromatic erythroblasts were detected by se-
lected gating (primary gate Hoechst vs Forward scatter
area; secondary—TMRM), and then isolated using a
BDInflux Cell Sorter.
Antibodies
Vimentin RV202 (ab8978; Abcam) for western blot, flow
cytometry and confocal microscopy; α-Globin (D-16,
Santa Cruz Biotechnology), Glycophorin A (CDVP,
IBGRL, UK), Band 3 (BRIC170, IBGRL, UK), β-actin
(Sigma), LC3B (Cell Signaling) and GABARAPL1 [28]
for western blot; and Glycophorin A (BRIC256, IBGRL,
UK) for confocal microscopy.
Whole-cell lysate preparation
Cultured cells were re-suspended in solubilisation buffer
(20 mM Tris HCl [pH 7.5], 150 mM NaCl, 10% glycerol,
1% Triton, 0.1% SDS, 1× complete protease inhibitor
and 2mM PMSF) and incubated for 1 h on ice before in-
cubation with 25 Uml−1 Bensonase for 1 h at 4 °C. Sam-
ples were centrifuged at 17,000g for 5 min at 4 °C and
supernatants collected. All chemicals were obtained
from Sigma-Aldrich.
Western blot
Membranes were blocked with 10% milk powder, incu-
bated overnight at 4 °C with primary antibody and
washed and incubated with secondary antibody (rabbit
α-mouse immunoglobulin-HRP; DakoCytomation) for 1
h at room temperature. Bands were visualized using en-
hanced chemilunescence (G.E. Healthcare).
PCR analysis
Primers (Sigma-Aldrich) used were forward: AAAT
GGCTCGTCACCTTCGT, reverse: TTGCGCTCC
TGAAAAACTGC for vimentin and forward: ACCA
CAGTCCATGCCATCAC, reverse: TCCACCACC
CTGTTGCTGTA for GAPDH with an annealing
temperature of 58 °C and 30 cycles.
Confocal microscopy
All procedures were as described previously [27].
Comparative proteomics
Comparative proteomics was performed using Tandem
Mass Tags (TMT) as described previously [5, 29] and
analysed using an Orbitrap Fusion Tribrid mass spec-
trometer (Thermo Scientific). Only rank 1 peptides with
high/medium confidence were used in analyses.
Vimentin knockdown
Cells were transduced with pLKO.1 short hairpin (sh)
RNA plasmids (sh19-23) against vimentin or with a
scrambled (src) control shRNA plasmid (all designed by
the Broad Institute and purchased from Open Biosys-
tems, GE Dharmacon, Lafayette, CO, USA) for 24 h.
Flow cytometry
Cells were fixed in 1% pararformaldehyde for 15 min be-
fore permeabilisation with 0.05% Triton X-100 for 5
mins. Cells were then blocked with 4% BSA before incu-
bation with vimentin antibody followed by rat
APC-conjugated anti-mouse IgG1 (Biolegend, London,
UK) and analysed on a MACSQuant system (Miltenyi
Biotech Ltd., Bisley, UK).
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Results
Expression profile of vimentin during adult erythropoiesis
To examine the expression profile of vimentin during
adult erythropoiesis, CD34+ cells isolated from periph-
eral blood were incubated in our three-stage culture sys-
tem which has previously been shown to achieve
efficient erythroid differentiation [2]. Morphological ana-
lysis from day 5 (Fig. 1a, Additional file 1: Figure S2A)
confirmed erythroid differentiation. By day 21 of culture,
~ 90% enucleation was routinely achieved. Maximum
proliferation occurred at the pro-erythroblast stage of
differentiation, but continued until approximately day 15
(Fig. 1b), in line with a final mitosis at the polychromatic
stage as determined previously [30]. We first examined
the relationship between vimentin expression and eryth-
roid differentiation by western blot. We found that
vimentin was present in cells at the early stages of eryth-
roid differentiation but then lost, coinciding temporally
with differentiation of basophilic to polychromatic eryth-
roblasts (Fig. 1c). We also examined the abundance of
vimentin by comparative proteomics. Tryptic peptides
generated from cells at days 3, 5, 8, 13 and 19 in culture
were labelled with different Tandem Mass Tags (TMT)
and analysed by nano LC-MS/MS, using methodology
described previously [5]. In line with the western blot, a
sharp drop (13-fold) in the level of vimentin occurred
between cells at day 8 in culture when the predominant
cell type is basophilic, and day 13 when the predominant
cell type is polychromatic (Fig. 1d). Negative controls,
i.e. proteins that did not change in level between day 8
to 13, include AHSP, ankyrin 1, aquaporin 1, band 4.2,
carbonic anhydrase 1, catalase, spectrin α and β and
tubulin β, as well as Glycophorin A in line with the
western blot data in Fig. 1c. We also interrogated our
proteomic data set for cells following enucleation (data
available in Wilson et al. [5]), detecting no vimentin pep-
tides in reticulocytes or endogenous mature RBCs. A
similar expression profile and magnitude decrease
(18-fold) in vimentin abundance on differentiation of
early basophilic to polychromatic erythroblasts was
found on interrogating the proteome dataset generated
by Gautier et al. [31], who compared the level of pro-
teins in adult erythroid cells isolated at distinct stages of
differentiation in vitro using label-free quantification.
D
CA
B
Fig. 1 Expression profile of vimentin during adult erythropoiesis Adult peripheral blood CD34+ cells were incubated for up to 21 days in a three-
stage erythroid culture system. a Cells were stained with May-Grünwald-Giemsa reagent at time points throughout the culture (see also
Additional file 1: Figure S1A) and the proportion of cells (Y-axis) at different stages of differentiation counted (data is representative of three
cultures). b Cell numbers at time points through erythropoiesis were counted and the cumulative fold expansion calculated n = 3 ± S.D. c
Western blot of adult erythroid cells at different days in culture probed with antibody to vimentin. An antibody to Glycophorin A was used as a
control. d The abundance of vimentin peptides at different time points in culture was compared by labelling with TMTs and analysis by nano LC-
MS/MS. Vimentin was quantified using 20 peptides with 47 PSM. e The abundance of vimentin transcripts at time points throughout erythroid
culture was analysed by PCR. Abundance of GAPDH transcripts was used as a control
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Vimentin protein is thus clearly lost when cells are
undergoing the final stages of terminal differentiation,
just prior to enucleation.
As vimentin is regulated at the transcriptional level
[19, 32], we also analysed the expression profile of
vimentin mRNA during adult erythropoiesis. Transcripts
were detected in early erythroid cells, but expression
then ceased (Fig. 1e), temporally coinciding with differ-
entiation of pro-erythroblasts to basophilic erythroblasts.
Expression of vimentin in erythroid cells differentiated
from ESC and iPSC
Avian erythroid cells are nucleated and retain vimentin
[25]. We therefore questioned whether erythroid cells
differentiated from ESC and iPSC also retain vimentin.
We have previously shown that CD34+ cells differenti-
ated from ESC line RC9 and iPSC line C19, used in the
present study, undergo erythroid differentiation and ex-
press key erythroid markers, with the majority of cells
failing to enucleate [4, 9].
Following the haematopoietic differentiation of RC9
cells in the present study, CD34+ cells were isolated and
transferred to our erythroid culture system. The cells
differentiated along the erythroid pathway (Fig. 2a, b; ex-
pression of GPA on day 13 in comparison with adult
erythroid cells is shown in Additional file 1: Figure S2B)
to orthochromatic erythroblasts, but the majority failed
to enucleate, as expected. Prolonged time in culture did
not result in any further enucleation; the cells instead
died. The expression of vimentin transcripts was ana-
lysed by PCR during erythroid differentiation, with ex-
pression retained throughout even in orthochromatic
erythroblasts (Fig. 2c). We confirmed the presence of
vimentin protein in the RC9-derived orthochromatic
erythroblasts by western blot (Fig. 2d), comparing with
cells at day 17 in adult culture and with isolated adult
orthochromatic erythroblasts (Additional file 1: Figure
S2C); the latter included for consistency as at day 17
there is a mixed population of orthochromatics and re-
ticulocytes present in adult cultures. No vimentin was
detected in the adult samples. We also detected vimen-
tin in orthochromatic erythroblasts differentiated from
the iPSC line C19 (Fig. 2d) using the same culture sys-
tem (Additional file 1: Figure S3 shows erythroid cell
morphology of C19 cells during differentiation). In
addition, comparative proteomics of C19 and adult
pro-erythroblasts and of C19 and adult isolated ortho-
chromatic erythroblasts show vimentin at an equivalent
level in the pro-erythroblasts but approximately 20-fold
higher in the iPSC compared to adult orthochromatic
A
B
DC
Fig. 2 Expression of vimentin in erythroid cells differentiated from the ESC line RC9 RC9 CD34+ cells were incubated for up to 19 days in a three-
stage erythroid culture system. a Cells were stained with May-Grünwald-Giemsa reagent at time points throughout the culture. White arrows, pro-
erythroblasts; blue arrows, basophillic erythroblasts; red arrows, polychromatic erythroblasts; black arrows, orthochromatic erythroblasts. (b) The
proportion of cells (Y-axis) at different stages of differentiation counted (data is representative of three cultures). c The abundance of vimentin
transcripts at time points throughout erythroid culture was analysed by PCR. Abundance of GAPDH transcripts was used as a control. d Cells at
day 17 in adult culture (orthochromatic erythroblasts and reticulocytes), isolated adult orthochromatic erythroblasts, RC9 and C19 orthochromatic
erythroblasts were probed with an antibody to vimentin. Blots were stripped, and an α-globin antibody used as a control for protein loading
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erythroblasts, supporting the data from western blot;
vimentin was quantified from 30 and 34 unique peptides
with 75 and 107 PSM respectively for these analyses.
Hence, vimentin is retained in both the ESC-derived and
iPSC-derived erythroid cells throughout erythropoiesis,
with the transcript data indicting dysregulation from the
early stage of terminal differentiation. Of note, we have
shown previously that both culture systems used in this
study result in the production of definitive, not primi-
tive, erythroid cells from both iPSC and ESC [4, 9].
Erythroid cells differentiated from the RC9 line differen-
tiate a little more rapidly than from the C19 line, as
shown by the morphological analysis (Fig. 2a, b, Add-
itional file 1: Figure S3A and B). However, erythroid cells
from both lines achieve efficient differentiation to ortho-
chromatic erythroblasts (Fig. 2a, b, Additional file 1: Fig-
ure S3A and B) with the level of GPA, Band 3 (key
erythroid differentiation markers) and α-globin increas-
ing during differentiation as expected (Additional file 1:
Figure S4).
Localisation of vimentin in erythroid cells
We also looked at the conformation of vimentin in adult
and C19 erythroblasts by confocal imaging on days 7, 14
and 21 of culture. Vimentin was detected in adult eryth-
roblasts only on day 7, but in C19 erythroblasts at all
time points. In all cells, detected vimentin appeared fila-
mentous in structure, surrounding the nucleus (Fig. 3A).
This is more clearly seen in the 3D reconstruction im-
ages shown in Fig. 3B for an adult erythroblast on day 7
(a), and C19 erythroblasts on days 7 (b), 14 (c) and 21
(d). In both the adult and C19 erythroblast populations,
only 20–30% vimentin-positive cells were routinely de-
tected. Heterogeneity in vimentin detection in popula-
tions of erythroid and MEL cells has been observed
previously [24] and may be due to antigen masking or
modification. Expression and conformation of vimentin
in erythroid cells differentiated from a second iPSC line;
OPM2 [4, 27] showed the same profile as the C19 eryth-
roblasts at the same time points in culture by confocal
analysis (data not shown).
Previous studies have shown the formation of an
F-actin structure [2, 29], more recently termed an enu-
cleosome [13], at the rear of the nucleus in enucleating
adult orthochromatic erythroblasts, which is believed to
generate the force required for nuclear extrusion. This
structure was observed in enucleating adult orthochro-
matic erythroblasts in our present study (example is
A B
C
Fig. 3 Localisation of vimentin in adult and C19 erythroid cells. The expression and conformation of vimentin in adult and C19 erythroblasts was
analysed by confocal microscopy on days 7, 14 and 21 of culture. a Cells were probed with a vimentin antibody, followed by Alexa Fluor 488
(green). Nuclear DNA was stained with blue-fluorescent DAPI. Images are representative of the overall cultures. b 3D reconstruction from the
images of adult erythroblasts on day 7 (a) and C19 erythroblasts on day 7 (b), 14 (c) and 21 (d). Images were reconstructed using velocity 6.1.1
software. c Orthochromatic erythrobasts from C19 cultures were incubated with vimentin antibody, followed by Alexa Fluor 488 (green) and
Alexa Fluor 635 phalloidin (red). Arrow indicates an enucleating erythroblast with enucleosome structure formation. Inset shows an adult
enucleating erythroblast with enucleosome. Scale bars 10 μm
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shown in Fig. 3C insert). In C19 orthochromatic erythro-
blasts at day 21 in culture co-labelled for vimentin and
F-actin, in vimentin-positive cells, F-actin was localized
around the cell periphery (Fig. 3C). However, in the rare
cells captured undergoing enucleation, vimentin was ab-
sent, and F-actin was localized to a similar enucleosome
structure (Fig. 3C, arrow). Although inconclusive be-
cause of the low enucleation rate and thus extremely
low number of cells undergoing enucleation at any one
time, it is tempting to speculate a link between vimentin
retention and failure of actin re-localisation, as the two
proteins are known to interact [33, 34]. Thus, a small
sub population of C19 erythroid cells may be correctly
programmed and are thus able to enucleate normally.
Knockdown of vimentin in C19 erythroid cells
Finally, we knocked down vimentin mRNA in C19
erythroid cells, selecting the time in culture when the
majority of cells were basophilic, to correlate with the
stage of differentiation vimentin transcripts are naturally
lost in adult cells (Fig. 1e). The efficiency of five vimen-
tin shRNAs was first verified in K562 cells (Add-
itional file 1: Figure S5A and B) with shRNA 21
reducing vimentin protein by the greatest amount (~
80%). C19 erythroid cells were transduced with this hair-
pin and knock down verified by fluorescent microscopy.
Unfortunately, vimentin knockdown stopped the cells
dividing resulting in cell death (Additional file 1: Figure
S5C); thus, we were unable to determine an effect on
enucleation. As vimentin loss occurs naturally in adult
erythroblasts and is clearly not detrimental, presumably
complexes and processes involving vimentin [17, 18, 33,
34] undergo prior or parallel reorganization, no longer
requiring vimentin. In contrast in C19 erythroid cells,
vimentin-dependent complexes may persist alongside
vimentin, resulting in their disruption when vimentin is
knocked down and thus the observed cell death. Simply
knocking vimentin down or out in these cells is there-
fore not a solution to correct the enucleation defect; in-
stead, the underlying dysregulation in these cells needs
to be determined.
Correlation of miR-30a expression with enucleation
To investigate the molecular basis of the enucleation de-
fect of ESC-derived erythroid cells, Rouzbeh et al. [35]
analysed gene and miRNA expression profiles, reporting
miR-30a as a key regulator of erythroblast enucleation
with aberrant overexpression responsible for the defect.
They showed that erythroid cells differentiated from
ESC line H1 day 20 embryoid bodies (EBs) achieved a
high enucleation rate of ~ 55%, but when differentiated
from day 9 EBs the rate dropped to ~ 1%. In cells differ-
entiated from day 9 EBs, miR-30a was aberrantly ele-
vated in late-stage erythroid cells. Subsequent
knockdown of miR-30a in these cells increased the enu-
cleation rate to ~ 51%. However, using a second ESC
line, H9, enucleation rates of erythroid cells differenti-
ated from day 20 EBs were only ~ 11%, in line with that
commonly achieved for many ESC and iPSC lines. Not-
withstanding, enucleation rates of erythroid cells differ-
entiated from H9 day 9 EBs of < 1% were increased to ~
10% on knockdown of miR-30a. Although not as strik-
ing, aberrant expression of this miRNA may contribute
to the defective enucleation process in these cells.
Interestingly, in other cell types, miR-30a has been
shown to downregulate the expression of vimentin [36–
38]. We therefore also investigated the expression of
miR-30a in erythroid cells differentiated from H1 early
EBs but did not find aberrantly elevated levels of
miR-30a, the expression profile during erythropoiesis de-
clining in line with that in adult erythroid cells (Fig. 4a)
and in erythroid cells from day 20 EB bodies in the
Rouzbeh et al. study [35]. The level of miR-30a was
however higher in the EBs than that in stage-matched
adult progenitors [8] (Fig. 4a). We therefore used the
same methodology as Rouzbeh et al. [35] to knock down
miR-30a in erythroid cells differentiated from day 9 EBs
and achieved reduced levels of miR-30a that were
retained throughout erythroid culture (Fig. 4b), but enu-
cleation remained negligible. Confirmation of the effect
of miR-30a knockdown was achieved by verifying in-
creased levels of miR-30a targets GABARAPL1 and
LC3B by western blot (Additional file 1: Figure S6).
During adult erythropoiesis, vimentin transcript
(Fig. 1e) and miR-30a levels (Fig. 4a) show a similar ex-
pression profile, with levels highest in early erythroid
cells and rapidly declining as cells differentiate further.
The miR-30a profile is also similar in cord blood eryth-
roid cells during erythropoiesis [35]. MiR-30a may there-
fore play a role in degradation of vimentin transcript in
these cells. However, any such association is clearly lost
in erythroid cells differentiated from ESCs, or the regula-
tion of vimentin by miR-30a could be context
dependent.
The discrepancy between our data and that of Rouz-
beh et al. may be due to different clones of H1 having
different expression profiles and thus behaviour in cul-
ture; however, our data demonstrate that modulation of
miR30a alone is not sufficient to promote enculeation in
ESC erythroid cells. Comparison between the clone with
high erythroid enucleation potential and those with low
enucleation rates could potentially be informative.
Discussion
In this study, we show that during normal adult human
erythropoiesis expression of vimentin is switched off
early during differentiation with the level of vimentin
protein declining strikingly at the late stage of terminal
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differentiation, just prior to enucleation. In contrast,
vimentin expression is maintained and vimentin protein
retained in erythroid cells differentiated from ESCs and
iPSCs. This clearly does not prevent these cells differen-
tiating to orthochromatic erythroblasts but may impede
the enucleation process resulting in or contributing to
the poor enucleation rates achieved for these cells.
Vimentin is also retained in avian erythrocytes, which
are nucleated, attributed to differences in cis-regulatory
elements between the mammalian and avian vimentin
gene [39]. Chicken vimentin mRNA levels increased sig-
nificantly on the differentiation of MEL cells transfected
with the entire chicken vimentin gene, whereas in cells
transfected with the hamster vimentin gene the corre-
sponding mRNA levels declined in line with the en-
dogenous murine vimentin mRNA. Conversely, in a
separate study, chicken vimentin was not detected in
mature erythrocytes from transgenic mice expressing the
chicken vimentin gene [40]. The regulatory mechanism
for retention of vimentin in avian erythroid cells is
therefore unresolved but does raise potentially interest-
ing parallels with vimentin and nuclear retention in
iPSC- and ESC-derived erythroid cells.
Notwithstanding, retention of vimentin, and other
anomalies of iPSC- and ESC-derived erythroid cells, may
not be due to inherent defects of the cells but to insuffi-
ciencies in the culture systems used. Our erythroid cul-
ture system supports efficient differentiation of adult
and cord blood stem cells, with up to 95% and 85% enu-
cleation respectively. Nevertheless, iPSC- and
ESC-derived CD34+ cells may require other factors to
induce correct terminal erythroid differentiation and
thus enucleation. It is also possible that conditions dur-
ing haematopoietic differentiation do not induce correct
programming of the resultant CD34+ cell, with greater
phenotypic analysis of these cells required. Either way,
whether inherent or environmental our data indicate
that defective programming of iPSC and ESC occurs
early in erythroid differentiation and may occur even
earlier during haematopoietic differentiation.
Conclusion
In conclusion, we show vimentin gene expression ceases
around the basophilic stage of differentiation in adult
erythropoiesis. Persistent expression of the vimentin
gene in iPSC and ESC erythroid cells from this stage in-
dicates dysregulation of transcription from at least this
stage of differentiation. In addition, selective nuclear
reorganization in erythroblasts, whereby selected genes
such as α- and β-globin and protein 4.1R continue to be
transcribed right up until nuclear extrusion despite
major transcriptional shut down [41], may be dysregu-
lated in iPSC and ESC erythroid cells enabling genes
such as vimentin to continue being transcribed to this
late stage.
Clearly, further investigation into the regulation of
gene and protein expression in iPSC- and ESC-derived
erythroid cells is required to understand and rectify their
enucleation defect. However, our data provide the first
evidence that dysregulation occurs at the early stages of
differentiation, helping direct future studies.
Additional file
Additional file 1: Supplementary figures and legends. Vimentin
expression is retained in erythroid cells differentiated from human iPSC
and ESC and indicates dysregulation in these cells early in differentiation.
(PPTX 28388 kb)
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